<DOC>
	<DOCNO>NCT00342355</DOCNO>
	<brief_summary>This study determine well four different antiretroviral drug therapy work patient advanced HIV disease . The trial part South Africa-U.S. Project Phidisa Programme - collaboration South African Military Health Service ( SAMHS ) South African National Defense Force ( SANDF ) , U.S. Department Defense , U.S. National Institutes Health - help prevent HIV transmission among South African military civilian employee family . Members SANDF HIV infection may eligible study . HIV-infected family member 14 year age older may also participate . All participant must CD4 count less 200 AIDS-defining illness . Participants randomly assign one follow four antiretroviral drug regimen , require take 5 pill every day : - AZT ( zidovudine ) + ddl ( didanosine ) + EFV ( efavirenz ) - AZT ( zidovudine ) + ddl ( didanosine ) + r/LPV ( lopinavir/ritonavir ) - D4T ( stavudine ) + 3TC ( lamivudine ) + EFV ( efavirenz ) - D4T ( stavudine ) + 3TC ( lamivudine ) + r/LPV ( lopinavir/ritonavir ) Patients follow 6 year . Clinic visit schedule month first 3 month every 3 month next five year . Patients undergo medical history , physical examination , blood test visit , complete questionnaire behavior , quality life , force readiness every year .</brief_summary>
	<brief_title>Antiretroviral Therapy Advanced HIV Disease South Africa</brief_title>
	<detailed_description>This randomize , open label 2x2 factorial study four regimens initial therapy . I. AZT + ddl + EFV II . AZT + ddl + r/LPV III . D4T + 3TC + EFV IV . D4T + 3TC + r/LPV Eligible patient commence randomly allocate study drug soon possible randomization . Episodes treatment limit toxicity manage keep protocol specify guideline . Patients experience treatment failure ( specify protocol ) manage change regimen correspond one treatment group .</detailed_description>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>INCLUSION CRITERIA : Uniformed SANDF personnel family member SANDF personnel register eligible health service SAMHS . HIV positive diagnose and/or confirm PHIDISA I OR document HIV infection accredit source . CD4+ cell count le 200 cells/microL ( less equal 14 % patient postsplenectomy ) AND/OR AIDS define illness currently historically . Patients pulmonary tuberculosis must CD4+ cell count le 200 cells/microL . Patients KS must CD4+ cell count le 200 cells/microL unless sarcoma progressive and/or require chemotherapy . Antiretroviral treatment naive ( less 7 day cumulative exposure antiretroviral drug ) treat postexposure prophylaxis without become HIV infected time . Laboratory variable follow : 1 . Haemoglobin great equal 9.0g/dL men great equal 8.0g/dL woman . 2 . Absolute neutrophil count great equal 500 cells/microL . 3 . Platelet count great equal 25,000/mm ( 3 ) . 4 . Serum transaminase ( ALT AST ) less equal 5 time upper limit normal ( ULN ) . 14 year old . Likely compliant study procedure clinical visit opinion clinical investigator ( guidance provide protocol assist clinician make decision ) . Have complete PHIDISA treatment adherence counsel session . Provision write informed consent . EXCLUSION CRITERIA : Any history pancreatitis serious pathology indicative increase risk pancreatitis . Current requirement use medication contraindicate PHIDISA II study drug . Where possible , alternate therapy select order facilitate randomization . Patients enter study tuberculosis defer screen randomization successful completion induction course antimycobacterium therapy include rifampicin . As appropriate patient could recommence screen start maintenance regimen antitubercular drug exclude rifampicin . Pregnancy ( follow delivery , woman may enrol ) .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Protease Inhibitors</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>AIDS</keyword>
	<keyword>Opportunistic Infections</keyword>
	<keyword>Resource-Poor</keyword>
</DOC>